NEW RELEASE

SPINTELLX, WHICH LEVERAGES AI FOR DIGITAL PATHOLOGY MARKETS, CLOSES SEED FINANCING AND LAUNCHES COMPANY

Seed Round Led by Newlin Investment Company, an Early-Stage Venture Capital Firm

PITTSBURGH, PA (September 10, 2018) – SpIntellx, Inc., a computational pathology company, today announced the recent closing of a seed financing round led by Newlin Investment Company, an early-stage venture capital firm. SpIntellx is applying its proprietary Artificial Intelligence (AI) technologies to develop computational tools based on spatial analytics for pathologists in all therapeutic areas, as well as in cancer for biopharma companies and other drug development organizations.

SpIntellx, which stands for spatial intelligence, has completed initial validation studies for its products in development: HistoMapr™ and TumorMapr™. HistoMapr, a computational guide for pathologists, automatically recognizes and classifies regions of interest in H&E-stained and/or immunohistochemistry slides, with the goal of improving the accuracy and efficiency of analysis and diagnostic decision-making by pathologists. The company’s other product, TumorMapr, analyzes the spatial interactions within whole slide images using multiplexed fluorescence. The goal of TumorMapr is to predict patient outcomes to better provide personalized therapeutic strategies, as well as to generate real-world evidence for developing prognostic and companion diagnostics.

“We are excited to partner with Newlin Investment Company to apply our computational pathology technologies to extend the power of digital pathology and to enable precision medicine,” stated D. Lansing Taylor, SpIntellx Chairman and Co-Founder.

The seed round, which was led by Newlin Investment Company, will be used to launch SpIntellx as it pursues strategic partnerships and further validation studies.

“Newlin Investment Company is extremely pleased to partner with Lans Taylor, the Director of the Pitt Drug Discovery Institute and a Professor of Computational & Systems Biology,” said Bill Newlin, Chairman of Newlin Investment Company. “Besides being a leading scientist, Lans is an experienced entrepreneur.”

“We are very excited about the tools SpIntellx is developing that leverage the power of AI to improve the accuracy of a pathologist’s diagnoses and prediction of a disease like cancer, and its progression. We believe in the work of the team at SpIntellx, and that it will help significantly improve patient outcomes by pinpointing the correct drug therapy.”
About SpIntellx:

SpIntellx, Inc., a computational pathology company based in Pittsburgh, applies its proprietary AI technologies to analyze whole slide image pathology samples based on spatial analytics. The company was co-founded by D. Lansing Taylor (Chairman), S. Chakra Chennubhotla (President), Jeffrey L. Fine, and Michael J. Becich, with licenses from the University of Pittsburgh. For more information on SpIntellx, please visit: www.spintellx.com

About Newlin Investment Company

Newlin Investment Company provides early stage and other capital to university technology spinouts across a variety of technologies. The firm is a private equity investor that makes long-term investments in selected growth and value opportunities in technology, industrial and retail markets. It works to create substantial value for its portfolio companies through a collaborative partnership that emphasizes strategic planning, team-building, financial and operational excellence. For more information on Newlin Investment Company, go to: www.NewlinInvestment.com.

Contact:
SpIntellx, Inc.
2425 Sidney Street
Pittsburgh, PA 15203
For inquiries, please email info@spintellx.com